MOLOGEN AG - Active immune therapies against cancer MGN1703 and MGN1601. video

Bit Index AI |

Broadcast Live | Upload & Publish |

About |

Close [ x ]

Forgotten Password?

You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.

3B PLAYER by 3B NEXUS

Close [ X ]

Copy this code to embed & stream this video on your website

<div id="svp_player1120735" style="width:636px;height:342px;"><strong>You need to install or upgrade your Flash Player!</strong><br><a href="http://www.macromedia.com/go/getflashplayer" target="_new"><img src="../../img/flash_link.gif" border="0" width="88" height="31"/></a>
	<p>3B NEXUS video platform & portal supports the latest version of  <a href="http://www.macromedia.com/go/getflashplayer" target="_new">Macromedia Flash</a> player.</p> 
	<hr/> <center><h3>3B PLAYER by <a href="/">3B NEXUS</a></center></div>
	<script language="JavaScript">
svp_clip_id = "1120735";
nexus_user_id = "";
svp_player_color1 = "#3399FF";
svp_player_color = "#010101";
svp_player_color_ratio = 1.0;
svp_player_height = "342";
svp_player_width = "636";
svp_transparent = "true";
svp_pause="1";
svp_stretch_video=1;
svp_start_volume="15";
svp_bg_color="#FFFFFF";
svp_fs_mode="2";
svp_no_fullscreen="0";
svp_no_controls="";
svp_auto_hide="1";
svp_skin="2";
svp_start_img="0";
svp_use_div="svp_player1120735";
</script>
<script language="JavaScript" type="text/javascript" src="../../js/eplayer.js"></script>

Copy this URL to share or create a link back to this video

MOLOGEN AG

Prof. Dr. Burghardt Wittig

Chairman, Scientific & Strategy Board

Germany

MOLOGEN AG - Active immune therapies against cancer MGN1703 and MGN1601.

MOLOGEN’S lead products are MGN1703 and MGN1601. MGN1703 is a DNA-based cancer immuno-therapy with an outstanding safety profile. The drug is currently being investigated in a clinical trial phase II/III for the treatment of metastatic colorectal cancer. MGN1601 is a cancer vaccine against renal cell caner. In a clinical phase I/II trial the drug demonstrated a very good tolerability and showed first efficacy.

Visit Website Disclaimer View Channel Factsheet Presentation Press Release

Please select a Media Channel	[ close ]
Please select the appropriate option to comply with legal regulations

Individual Investor

Professional Investor or Financial Advisor

This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only.

This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.

* I comply with these terms

Remember my choice for all channels on this portal

Enter Media Channel »

No reliance should be placed on the information on this site which may change without notice.

You should read the Terms & Conditions section before browsing this site.